|

Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk

RECRUITINGSponsored by Abramson Cancer Center at Penn Medicine
Actively Recruiting
SponsorAbramson Cancer Center at Penn Medicine
Started2015-05
Est. completion2028-05
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT02478892

Summary

The study is a prospective, observational study evaluating the utility of endoscopic ultrasound or MRI for the identification of preneoplastic and neoplastic pancreatic lesions in patients at high risk for pancreatic cancer, specifically those with BRCA1/2, ATM, or PALB2 mutations.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria

* Age \>= 18
* Documented germline pathogenic or likely pathogenic BRCA1, BRCA2, ATM, or PALB2 mutation
* If no history of PDAC in a first or second degree relative, age \>= 50
* If there is a history of PDAC in a first or second degree relative, minimum age of eligibility is 10 years younger than the age of onset of the youngest relative with pancreatic cancer

Exclusion Criteria

• Pregnancy

Conditions2

CancerPancreatic Cancer

Locations1 site

Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19004
Bryson Katona, MD855-216-0098Bryson.Katona@pennmedicine.upenn.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.